BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
Molecules · 29.03.2023 · 28 (7) · 3043
DOI: 10.3390/molecules28073043 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 29.03.2023. Verfasst von Kenneth K W To und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 212 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The mammalian bromodomain and extra-terminal domain (BET) family of proteins consists of four conserved members (Brd2, Brd3, Brd4, and Brdt) that regulate numerous cancer-related and immunity-associated genes. They are epigenetic readers of histone acetylation with broad specificity. BET proteins are linked to cancer progression due to their interaction with numerous cellular proteins including chromatin-modifying factors, transcription factors, and histone modification enzymes. The spectacular growth in the clinical development of small-molecule BET inhibitors underscores the interest and importance of this protein family as an anticancer target. Current approaches targeting BET proteins for cancer therapy rely on acetylation mimics to block the bromodomains from binding chromatin. However, bromodomain-targeted agents are suffering from dose-limiting toxicities because of their effects on other bromodomain-containing proteins. In this review, we provided an updated summary about the evolution of small-molecule BET inhibitors. The design of bivalent BET inhibitors, kinase and BET dual inhibitors, BET protein proteolysis-targeting chimeras (PROTACs), and Brd4-selective inhibitors are discussed. The novel strategy of targeting the unique C-terminal extra-terminal (ET) domain of BET proteins and its therapeutic significance will also be highlighted. Apart from single agent treatment alone, BET inhibitors have also been combined with other chemotherapeutic modalities for cancer treatment demonstrating favorable clinical outcomes. The investigation of specific biomarkers for predicting the efficacy and resistance of BET inhibitors is needed to fully realize their therapeutic potential in the clinical setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
- Department of Cancer Biology and Genetics, College of Medicine, and Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
ORCID-Profile: Kenneth K W To, Ross C Larue
Zitieren
APA
To, K. K. W., Xing, E., Larue, R. C., & Li, P. K. (2023). BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules, 28(7), 3043. https://doi.org/10.3390/molecules28073043
Vancouver
To KKW, Xing E, Larue RC, Li PK. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules. 2023;28(7):3043. doi:10.3390/molecules28073043
BibTeX
@article{To2023,
author = {To, Kenneth K W and Xing, Enming and Larue, Ross C and Li, Pui-Kai},
title = {BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications},
journal = {Molecules},
year = {2023},
volume = {28},
number = {7},
pages = {3043},
doi = {10.3390/molecules28073043}
}
EUVIMED